osimertinib,lazertinib,amivantamab
astrazeneca,yuhan corp,oscotec,janssen,genmab
['lcsm,(-blcsm)', 'osimertinib', 'lazertinib', 'sclc', 'nsclc']
amivantamab + lazertinib combo looking promising in treating egfr+m nsclc after progression on either 1l or 2l osimertinib. combo seems effective in controlling untreated brain mets. a new "what's next after osi?" dr. catherine shu #lcsm #asco22 
LUNGevity Foundation is dedicated to funding lung cancer research and providing support to ALL people affected by lung cancer.